Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents.
Antiplatelet agents remain the cornerstone in the primary and secondary therapeutic intervention for cardiovascular disease. Some patients may be subjected to a year or more of dual antiplatelet therapy to reduce the risk of subsequent cardiovascular events. Patients on antiplatelet therapy have an increased risk of gastrointestinal bleeding; however, not all patients benefit from concomitant acid suppressive therapy. This review will provide an overview of the pharmacology of antiplatelet agents and outline patient risk profiles that ought to be considered when considering prophylactic therapy to reduce gastrointestinal toxicity. In addition, we discuss the current risk-reduction strategies intended to mitigate against the potential for related gastroduodenal injury.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tulane University, New Orleans, LA, USA.
Parth J
PJ
Parekh
Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA, USA.
Edward C
EC
Oldfield
Division of Gastroenterology, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA, 23510, USA. dajevms@aol.com.
David A
DA
Johnson
D002318:Cardiovascular Diseases / Q000188:drug therapy; D006471:Gastrointestinal Hemorrhage / Q000150:complications / Q000517:prevention & control*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors
D010975:Platelet Aggregation Inhibitors